Claritin, Linens Make Strange Bedfellows But Licensing Revenue For Merck
This article was originally published in The Tan Sheet
Executive Summary
Merck has a strategy for squeezing more juice out of an OTC brand in an increasingly competitive market segment: out-licensing to non-drug products